ATE213165T1 - Pharmazeutische zusammensetzung enthaltend wachstumshormon und wachstumshormon- bindungsprotein - Google Patents

Pharmazeutische zusammensetzung enthaltend wachstumshormon und wachstumshormon- bindungsprotein

Info

Publication number
ATE213165T1
ATE213165T1 AT95110334T AT95110334T ATE213165T1 AT E213165 T1 ATE213165 T1 AT E213165T1 AT 95110334 T AT95110334 T AT 95110334T AT 95110334 T AT95110334 T AT 95110334T AT E213165 T1 ATE213165 T1 AT E213165T1
Authority
AT
Austria
Prior art keywords
binding protein
hormone
growth hormone
bound
growth
Prior art date
Application number
AT95110334T
Other languages
English (en)
Inventor
Lena Mariana Susann Carlsson
Ross Graham Clark
Wai Lee Tan Wong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE213165T1 publication Critical patent/ATE213165T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
AT95110334T 1990-11-19 1991-11-19 Pharmazeutische zusammensetzung enthaltend wachstumshormon und wachstumshormon- bindungsprotein ATE213165T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/615,538 US5210017A (en) 1990-11-19 1990-11-19 Ligand-mediated immunofunctional hormone binding protein assay method

Publications (1)

Publication Number Publication Date
ATE213165T1 true ATE213165T1 (de) 2002-02-15

Family

ID=24465822

Family Applications (3)

Application Number Title Priority Date Filing Date
AT95110334T ATE213165T1 (de) 1990-11-19 1991-11-19 Pharmazeutische zusammensetzung enthaltend wachstumshormon und wachstumshormon- bindungsprotein
AT92901281T ATE138739T1 (de) 1990-11-19 1991-11-19 Durch den liganden vermitteltes immunofunktionelles verfahren zur bestimmung hormonbindender proteine
AT99123825T ATE425764T1 (de) 1990-11-19 1991-11-19 Verwendung von igf-1 allein oder kombiniert mit dem wachstumsfaktor zur stimulierung des wachstums

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT92901281T ATE138739T1 (de) 1990-11-19 1991-11-19 Durch den liganden vermitteltes immunofunktionelles verfahren zur bestimmung hormonbindender proteine
AT99123825T ATE425764T1 (de) 1990-11-19 1991-11-19 Verwendung von igf-1 allein oder kombiniert mit dem wachstumsfaktor zur stimulierung des wachstums

Country Status (12)

Country Link
US (1) US5210017A (de)
EP (3) EP0558647B1 (de)
JP (2) JP2977280B2 (de)
AT (3) ATE213165T1 (de)
AU (1) AU657109B2 (de)
CA (1) CA2093927C (de)
DE (3) DE69132931T2 (de)
DK (3) DK0681842T3 (de)
ES (3) ES2090598T3 (de)
GR (1) GR3020505T3 (de)
HK (1) HK1007351A1 (de)
WO (1) WO1992008985A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866350A (en) * 1985-03-19 1999-02-02 Helen Hwai-An Lee Method for the immunological determination of a biological material in a sample
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US6326154B1 (en) * 1990-11-19 2001-12-04 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5593844A (en) * 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5464757A (en) * 1991-01-15 1995-11-07 The Salk Institute For Biological Studies DNA encoding CRF binding protein
NZ255158A (en) * 1992-07-31 1997-09-22 Genentech Inc Human growth hormone; stable pharmaceutically acceptable aqueous formulation and means for preparing and storing it
US6087188A (en) * 1992-11-13 2000-07-11 Alk A/S Two-site immunoassay for an antibody with chemiluminescent label and biotin bound ligand
DE69423436T2 (de) * 1993-06-25 2000-09-07 Smithkline Beecham P.L.C., Brentford An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US7885697B2 (en) 2004-07-13 2011-02-08 Dexcom, Inc. Transcutaneous analyte sensor
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AU762351B2 (en) * 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
US7108993B2 (en) * 2002-07-19 2006-09-19 Bayer Healthcare Llc Use of dual conjugated labels in the elimination of serum interference in immunochromatographic assays
SE0300959D0 (sv) * 2002-12-19 2003-04-02 Pharmacia Ab Methods for predicting therapeutic response to agents acting on the growth hormone receptor
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
PL2274978T3 (pl) 2003-09-12 2015-11-30 Ipsen Biopharmaceuticals Inc Sposoby leczenia niedoboru insulinopodobnego czynnika wzrostu 1 (IGF-1)
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US20070045902A1 (en) 2004-07-13 2007-03-01 Brauker James H Analyte sensor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE263537C (de) *
NL7501215A (nl) * 1975-02-01 1976-08-03 Akzo Nv Methode voor het aantonen en bepalen van een antigeen of antilichaam.
US4486530A (en) * 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4476228A (en) * 1982-11-08 1984-10-09 Abbott Laboratories Determination of unsaturated thyroxine binding protein sites using fluorescence polarization techniques
US4622293A (en) * 1983-07-05 1986-11-11 Miles Laboratories, Inc. Iodothyronine immunoassays employing HMS as TBP blocking agent
US4594327A (en) * 1983-11-02 1986-06-10 Syntex (U.S.A.) Inc. Assay method for whole blood samples
WO1985003357A1 (en) * 1984-01-30 1985-08-01 Icrf Patents Ltd. Improvements relating to growth factors
US4737456A (en) * 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
JPS63273496A (ja) * 1987-05-01 1988-11-10 Sumitomo Pharmaceut Co Ltd モノクロ−ナル抗体、ハイブリド−マおよびヒト成長ホルモン測定方法
US5057417A (en) * 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
DD263537A1 (de) * 1987-09-01 1989-01-04 Akad Wissenschaften Ddr Verfahren zur herstellung von monoklonalen antikoerpern gegen humanes wachstumshormon
US4956302A (en) * 1987-09-11 1990-09-11 Abbott Laboratories Lateral flow chromatographic binding assay device
EP0404783A4 (en) * 1988-01-28 1991-01-23 E.I. Du Pont De Nemours And Company Immunoassays using monoclonal antibodies directed against natural binding proteins
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
JPH03504597A (ja) * 1988-04-12 1991-10-09 シナージェン，インコーポレーテッド インスリン様成長因子活性の強化および阻害方法
CA1341598C (en) * 1988-07-15 2009-09-29 Central Sydney Area Health Service Acid-labile sub-unit (als) of insulin-like growth factor binding proteincomplex
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
EP0429586B1 (de) * 1989-06-09 1995-08-02 Gropep Pty. Ltd. Wachstumshormonfusionsproteine
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy

Also Published As

Publication number Publication date
WO1992008985A3 (en) 1992-10-29
CA2093927A1 (en) 1992-05-20
DK0558647T3 (da) 1996-08-19
AU657109B2 (en) 1995-03-02
DE69132931D1 (de) 2002-03-21
ES2324322T3 (es) 2009-08-04
EP0995445A2 (de) 2000-04-26
AU9106791A (en) 1992-06-11
DE69133614D1 (de) 2009-04-30
EP0681842A3 (de) 1998-06-10
US5210017A (en) 1993-05-11
ATE425764T1 (de) 2009-04-15
JP3159966B2 (ja) 2001-04-23
EP0681842B1 (de) 2002-02-13
DE69132931T2 (de) 2002-11-28
EP0681842A2 (de) 1995-11-15
EP0558647B1 (de) 1996-05-29
DE69119911D1 (de) 1996-07-04
EP0995445B1 (de) 2009-03-18
DE69119911T2 (de) 1996-11-21
EP0995445A3 (de) 2004-01-07
DK0995445T3 (da) 2009-07-06
ATE138739T1 (de) 1996-06-15
WO1992008985A2 (en) 1992-05-29
ES2090598T3 (es) 1996-10-16
HK1007351A1 (en) 1999-04-09
JP2977280B2 (ja) 1999-11-15
DK0681842T3 (da) 2002-06-03
EP0558647A1 (de) 1993-09-08
JPH11346765A (ja) 1999-12-21
ES2171478T3 (es) 2002-09-16
CA2093927C (en) 2000-07-18
JPH06502724A (ja) 1994-03-24
GR3020505T3 (en) 1996-10-31

Similar Documents

Publication Publication Date Title
ATE213165T1 (de) Pharmazeutische zusammensetzung enthaltend wachstumshormon und wachstumshormon- bindungsprotein
VAN WYK et al. Evidence from radioligand assays that somatomedin-C and insulin-like growth factor-I are similar to each other and different from other somatomedins
Jonas et al. The human placenta contains two distinct binding and immunoreactive species of insulin-like growth factor-I receptors.
EE05539B1 (et) Hbriidvalk, selle kasutamine, seda sisaldav antikeha v?i selle fragment ja selle kasutamine
DE68929151D1 (de) Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
Tigyi et al. A factor that activates oscillatory chloride currents in Xenopus oocytes copurifies with a subfraction of serum albumin.
ATE120374T1 (de) Markierte polypeptidderivate.
IL96043A0 (en) Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known
DE60129239D1 (de) Kit und verfahren zur bestimmung von protein esm-1
Gargosky et al. Characterization of insulin-like growth factor-binding proteins in rat serum, lymph, cerebrospinal and amniotic fluids, and in media conditioned by liver, bone and muscle cells
CA2291983A1 (en) Ligand-mediated immunofunctional hormone binding protein assay method
DE69121861D1 (de) Peptide von sm-d-antigen, deren benützung zum nachweis von disseminierten lupus-erythemateux
Hunter Homogeneity studies on human growth hormone
Smith et al. A parotid salivary protein present during late pregnancy and postpartum
Yalow et al. Radioimmunoassay of somatomedin B
Roholt et al. A light chain tyrosyl sequence in the antibody site of a rabbit anti-p-azobenzoate antibody
DK0439797T3 (da) Et antistof mod det carboxyl-terminale peptid af rotte-somatotropin-bindende protein
Carlsson et al. Ligand-mediated immunofunctional hormone binding protein assay method
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)
Losa et al. Evidence for a nonspecific factor interfering in the radioimmunoassay of somatoliberin-like immunoreactivity in human seminal plasma
Lasne et al. MICROHETEROGENEITY AND POLYMORPHISM OF THYROXINE-BINDING GLOBULIN
ATE291232T1 (de) Immunoassay von c-peptid-enthaltenden verunreinigungen in rekombinantem human-insulin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0681842

Country of ref document: EP

EELA Cancelled due to lapse of time